Surfagen is focused on the development of novel nanoparticle systems for the delivery of siRNA therapeutics. siRNA therapeutics, a recently developed approach for treating major diseases, has created a great deal of excitement because of its potential to impact the genes responsible for a wide variety of medical problems. As a result, a great deal of money has been invested, both by major pharmaceutical companies and private investors, in new companies that are developing siRNA therapeutics. However, one problem that has prevented siRNA from reaching its potential is the lack of a good delivery system. Surfagen , Inc. is developing a new class of novel multifunctional carriers (MFCs) that overcome the deficiencies of delivery systems for siRNA therapeutics being used by other companies.
